Show simple item record

dc.contributor.authorDréan, Aen_US
dc.contributor.authorLord, CJen_US
dc.contributor.authorAshworth, Aen_US
dc.date.accessioned2017-03-27T09:56:11Z
dc.date.issued2016-12en_US
dc.identifier.citationCritical reviews in oncology/hematology, 2016, 108 pp. 73 - 85en_US
dc.identifier.issn1040-8428en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/532
dc.identifier.eissn1879-0461en_US
dc.identifier.doi10.1016/j.critrevonc.2016.10.010en_US
dc.description.abstractIn 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.en_US
dc.formatPrint-Electronicen_US
dc.format.extent73 - 85en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAnimalsen_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectPoly(ADP-ribose) Polymerasesen_US
dc.subjectDrug Combinationsen_US
dc.subjectImmunotherapyen_US
dc.subjectPoly(ADP-ribose) Polymerase Inhibitorsen_US
dc.titlePARP inhibitor combination therapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-10-26en_US
rioxxterms.versionofrecord10.1016/j.critrevonc.2016.10.010en_US
rioxxterms.licenseref.startdate2016-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCritical reviews in oncology/hematologyen_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function
pubs.publication-statusPublisheden_US
pubs.volume108en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamGene Functionen_US
dc.contributor.icrauthorLord, Christopheren_US
dc.contributor.icrauthorDrean, Amyen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record